Relationship between expression of β3-adrenoceptor mRNA in bladder mucosa and urodynamic findings in men with lower urinary tract symptoms.
OBJECTIVE
To investigate the relationship between urinary bladder mucosal expression of β3-adrenoceptor (AR) mRNA and urodynamic findings in patients with lower urinary tract symptoms and benign prostatic obstruction (BPO).


METHODS
During surgical prostate resection of 32 BPO patients, mucosal biopsies were collected and analyzed by reverse transcriptase polymerase chain reaction to determine the expression level of β3-AR mRNA. First desire to void (FDV) and strong desire to void (SDV), detrusor overactivity (DO), and bladder outlet obstruction (BOO) were measured pre-operatively. Patients with FDVs < 200 ml or SDVs < 300 ml were assigned to the small capacity group (n = 19). Patients with FDVs > 201 ml and SDVs > 301 ml were assigned to the large capacity group (n = 13). The same patients with positive DO were also assigned to the DO+ group (n = 11), and those with negative DO were assigned to the DO- group (n = 21). Finally, patients whose position on the Schäfer nomogram was greater than degree V were assigned to the severe BOO group (n = 17), while those with less than degree IV were assigned to the mild BOO group (n = 15).


RESULTS
The expression level of β3-AR mRNA was similar in both bladder capacity groups and both DO groups. However, the expression level in the severe BOO group was significantly less than in the mild BOO group (P = 0.043).


CONCLUSIONS
The expression of bladder mucosal β3-AR mRNA was significantly decreased in patients with severe BOO, suggesting that β3-ARs might be affected by the degree of BOO.
Department of Urology, Shinshu University School of Medicine, Matsumoto, Japan.
Yoshiki
Y
Kurizaki
Osamu
O
Ishizuka
Tetsuya
T
Imamura
Masakuni
M
Ishikawa
Midori
M
Ichino
Teruyuki
T
Ogawa
Osamu
O
Nishizawa
Karl-Erik
KE
Andersson
D000368:Aged; D006801:Humans; D059411:Lower Urinary Tract Symptoms / Q000378:metabolism* / Q000503:physiopathology / Q000601:surgery; D008297:Male; D009092:Mucous Membrane / Q000378:metabolism / Q000473:pathology; D009130:Muscle, Smooth / Q000378:metabolism / Q000473:pathology; D011467:Prostate / Q000378:metabolism / Q000473:pathology; D011470:Prostatic Hyperplasia / Q000378:metabolism / Q000473:pathology / Q000601:surgery; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D022702:Receptors, Adrenergic, beta-3 / Q000235:genetics / Q000378:metabolism*; D012720:Severity of Illness Index; D001743:Urinary Bladder / Q000378:metabolism* / Q000473:pathology; D001748:Urinary Bladder Neck Obstruction / Q000378:metabolism* / Q000473:pathology / Q000601:surgery; D014563:Urodynamics / Q000502:physiology*
D012333:RNA, Messenger; D022702:Receptors, Adrenergic, beta-3